Clinical Research Directory
Browse clinical research sites, groups, and studies.
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
Sponsor: Brii Biosciences Limited
Summary
This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.
Official title: A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
86
Start Date
2023-08-22
Completion Date
2026-02
Last Updated
2025-09-05
Healthy Volunteers
No
Conditions
Interventions
PEG-IFNα
PEG-IFNα will be given via subcutaneous injection
BRII-835
BRII-835 will be given via subcutaneous injection
Locations (29)
Investigative Site 61001
Kingswood, New South Wales, Australia
Investigative Site 61002
Birtinya, Queensland, Australia
Investigative Site 61003
Melbourne, Victoria, Australia
Investigative Site 86001
Beijing, Beijing Municipality, China
Investigative Site 86001
Beijing, Beijing Municipality, China
Investigative Site 86007
Beijing, Beijing Municipality, China
Investigative Site 86004
Chongqing, Chongqing Municipality, China
Investigative Site 86006
Guangzhou, Guangdong, China
Investigative Site 85201
Hong Kong, HONG KONG, China
Investigative Site 85202
Hong Kong, HONG KONG, China
Investigative Site 86008
Changchun, Jilin, China
Investigative Site 86013
Shanghai, Shanghai Municipality, China
Investigative Site 88601
Kaohsiung, Taiwan, China
Investigative Site 88602
Taipei, Taiwan, China
Investigative Site 88603
Taipei, Taiwan, China
Investigative Site 86011
Hangzhou, Zhengjiang, China
Investigative Site 65001
Singapore, Singapore
Investigative Site 65002
Singapore, Singapore
Investigative Site 82002
Chuncheon, Chuncheon-si, South Korea
Investigative Site 82001
Busan, South Korea
Investigative Site 82004
Daegu, South Korea
Investigative Site 82005
Seoul, South Korea
Investigative Site 82003
Seoul, South Korea
Investigative Site 82006
Soeul, South Korea
Investigative Site 66003
Bangkok, Thailand
nvestigative Site 66007
Chiang Mai, Thailand
Investigative Site 66005
Khon Kaen, Thailand
Investigative Site 66006
Nonthaburi, Thailand
Investigative Site 66008
Songkhla, Thailand